Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several...

Description complète

Détails bibliographiques

Auteurs principaux:	Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini
Format:	Artigo
Langue:	Inglês
Publié:	PAGEPress Publications 2025-07-01
Collection:	Dermatology Reports
Sujets:	Psoriasis risankizumab erythrodermic psoriasis safety efficacy
Accès en ligne:	https://www.pagepress.org/journals/dr/article/view/10379
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!